SEC Form 4 · accession 0001179110-18-013361
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy A Simonian
Officer — President & CEO · Director
Period of report
Nov 29, 2018
Accepted (ET)
Dec 3, 2018 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 29, 2018 | M | 98,504 | $1.01 | A | 469,204 | D | |
| Common Stock | Nov 29, 2018 | M | 12,084 | $3.04 | A | 481,288 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.01 | Nov 29, 2018 | M | 23,454 | A | — | May 21, 2023 | Common Stock | 23,454 | 872,657 | D |
| Stock Option (right to buy)F1 | $1.01 | Nov 29, 2018 | M | 75,050 | A | — | May 21, 2023 | Common Stock | 75,050 | 797,607 | D |
| Stock Option (right to buy)F1 | $3.04 | Nov 29, 2018 | M | 12,084 | A | — | Oct 21, 2024 | Common Stock | 12,084 | 785,523 | D |
Explanation of responses
- F1This option is fully vested.